Table 1 Characteristics of studies included
Trial | Sample size (T/C) | Age, years (T/C) | Male gender (%) | Diagnosis | Follow-up |
Bamdad et al. (2015) [34] | 16/16 | 39.6 ± 16.8/40.3 ± 14.9 | 21 (66%) | BK | 1 month |
Uddaraju et al. (2015) [35] | 6/7 | 39.5 (35–41)/56 (40–62) | 8 (61%) | FK | 6 weeks |
Kasetsuwan et al. (2016) [36] | 15/15 | 44.60 (17–73)/53.93 (15–84) | 21 (70%) | BK/FK (12/18) | 1 month |
Wei et al. (2019) [11] | 21/20 | 53.4 ± 2.65/54.75 ± 3.67 | 26 (63%) | FK | 6 months |
Prajna et al. (2020) [12] | 55/56 | 55 (47, 65), 56 (45, 65)/50 (36, 55), 45 (40, 58) | 63 (57%) | FK | 3Â months |
Jeyalatha et al. (2021) [13] | 9/11 | 49 ± 13.3/50 ± 9.1 | 16 (80%) | FK | 1 month |
Prajna et al. (2021) [14] | 17/19 | 59 (48–66)/60 (54.5–65) | 21 (58%) | BK | 3 months |
Trial | PACK-CXL treatment protocol | SAT regimen | |||
Bamdad et al. (2015) [34] | The same day before SAT | 365 nm × 3 mW/cm2 × 30 min | Cefazolin, gentamicin | ||
Uddaraju et al. (2015) [35] | After SAT for 2 weeks | 370 nm × 3 mW/cm2 × 30 min | Natamycin, voriconazole | ||
Kasetsuwan et al. (2016) [36] | The same day before SAT | 365 nm × 3 mW/cm2 × 30 min | Cefazolin, amikacin; amphotericin B, natamycin | ||
Wei et al. (2019) [11] | The same day before SAT | 365 nm × 3 mW/cm2 × 30 min | Natamycin, voriconazole | ||
Prajna et al. (2020) [12] | Within 24 h of enrollment | 365 nm × 3 mW/cm2 × 30 min | Natamycin, voriconazole | ||
Jeyalatha et al. (2021) [13] | Not reported | 370 nm × 3 mW/cm2 × 30 min, 5.4 J/cm2 | Natamycin, voriconazole/amphotericin B | ||
Prajna et al. (2021) [14] | Within 24 h of enrollment | 365 nm × 3 mW/cm2 × 30 min | Moxifloxacin | ||